Pharmacodynamic interaction between RP 59500 and gram-positive bacteria infecting fibrin clots
- 1 October 1992
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 36 (10) , 2211-2215
- https://doi.org/10.1128/aac.36.10.2211
Abstract
The fibrin clot penetration and in vivo bactericidal activity of RP 59500, a new semisynthetic streptogramin, for two Staphylococcus aureus strains (one methicillin resistant and the other methicillin susceptible), two Staphylococcus epidermidis strains (one methicillin resistant and the other methicillin susceptible), and one Enterococcus faecalis strain were evaluated. The clots, inserted subcutaneously, were infected with a mean of 10(8) CFU of the pathogen per g. For each strain, groups of four rabbits received a single intravenous injection of 50 mg of RP 59500 per kg of body weight over 30 min. The mean peak level of RP 59500 in serum in the infected rabbits was 61.9 +/- 6.3 micrograms/ml. The drug was detectable in serum at a level of 0.8 micrograms/ml up to 4 h after administration. The mean peak fibrin clot drug level at 1 h was 3.3 +/- 0.1 micrograms/g. At 6 h, the level in clots was 1.2 +/- 0.1 micrograms/g. The mean half-life in serum in infected rabbits was 0.34 +/- 0.01 h, while in clots the drug exhibited a longer half-life of 3.8 +/- 0.4 h. In vivo, this new streptogramin sterilized the clots infected with the two S. aureus strains studied in less than 1 h and induced a marked reduction in colony counts of the two S. epidermidis strains studied for up to 24 h. The activity of the streptogramin against E. faecalis was limited. These results suggest that RP 59500 should be further evaluated for the treatment of infection with methicillin-resistant staphylococci.Keywords
This publication has 8 references indexed in Scilit:
- In vitro activity of RP 59500, a semisynthetic injectable pristinamycin, against staphylococci, streptococci, and enterococciAntimicrobial Agents and Chemotherapy, 1991
- Phenotypic and genotypic heterogeneity of glycopeptide resistance determinants in gram-positive bacteriaAntimicrobial Agents and Chemotherapy, 1990
- Ampicillin-resistant enterococcal species in an acute-care hospitalAntimicrobial Agents and Chemotherapy, 1990
- Single oral dose pharmacokinetics of the two main components of pristinamycin in humansJournal of Antimicrobial Chemotherapy, 1989
- The in-vitro activity, pharmacokinetics and tissue penetration of temafloxacinJournal of Antimicrobial Chemotherapy, 1989
- Emergence of Vancomycin Resistance in Coagulase-Negative StaphylococciNew England Journal of Medicine, 1987
- Influence of four modes of administration on penetration of aztreonam, cefuroxime, and ampicillin into interstitial fluid and fibrin clots and on in vivo efficacy against Haemophilus influenzaeAntimicrobial Agents and Chemotherapy, 1985
- Continuous vs. Intermittent Administration of Antimicrobial Agents: Tissue Penetration and Efficacy in VivoClinical Infectious Diseases, 1981